Current Problems in Cancer
Volume 26, Issue 4 , Pages 176-275 , July 2002

Pancreatic cancer

References 

  1. American Cancer . Society: facts and figures. Atlanta: : American Cancer Society; 2002;
  2. Greenlee R, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  3. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996;23:241–250
  4. Sohn TA, Yeo CJ, Cameron JL, Koniarais L, Kaushal S, Abrams R, et al.  Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579
  5. Birkmeyer J, Siewers A, Finlayson E, Stukel T, Lucas L, Batista I, et al.  Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137
  6. Devesa S, Blot W, Stone B. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182
  7. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am. 1998;7:67–91
  8. National Center for Health Statistics . Health, United States, 2000 with Urban and Rural Chartbook. Hyattsville, MD: : Public Health Service; 2001;
  9. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, et al.  Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830–1837
  10. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433–1437
  11. Offerhaus GJA, Tersmette AC, Tytgat GNJ, Hoedemaeker PJ, Vandenbroucke JP. Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism. Mod Pathol. 1988;1:352–356
  12. Mulder I, van Genugten MLL, Hoogenveen R, de Hollander AEM, Bueno-de-Mesquita HB. The impact of smoking on future pancreatic cancer: a computer simulation. Ann Oncol. 1999;10:S74–S78
  13. Wynder E. An epidemiological evaluation of the causes of cancer of the pancreas. Cancer Res. 1975;35:2228–2233
  14. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605–1609
  15. Gapstur S, Gann P, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283:1512–1523
  16. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286:921–929
  17. Ghadirian P, Liu G, Gallinger S, Schmocker B, Paradis AJ, Lal G, et al.  Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer. 2002;97:807–810
  18. Tersmette AC, Petersen GM, Offerhaus GJA, Falatko FC, Goggins M, Rosenblum E, et al.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001;7:738–744
  19. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 2000;11:915–923
  20. Klein AP, Petersen GM, Beaty TH, Bailey-Wilson JE, Hruban RH. Statistical evidence for a novel major gene involved in pancreatic cancer. Genetic Epidemiology. 2002;23:133–149
  21. Cancer risks in BRCA2 mutation carriers: the Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999;91:1310–1316
  22. Murphy KM, Brune KA, Griffin CA, Hruban RH, Kern SE. Candidate genes MAP2K4, MADH4, and BRCA2 in familial pancreatic cancer. Cancer Res. 2002;62:3789–3793
  23. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364
  24. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260–1266
  25. Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, et al.  Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer. 2002;94:84–96
  26. Giardello FM, Welsh SB, Hamilton SR, et al.  Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511–1514
  27. Lynch HT, Voorhees GJ, Lanspa S, McGreevy PS, Lynch J. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer. 1985;52:271–273
  28. Goggins M, Offerhaus GJA, Hilgers W, Griffin CA, Shekher M, Tang D, et al.  Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998;152:1501–1507
  29. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich C, et al.  Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141–145
  30. Lowenfels AB, Maisonneuve EP, Dimagno YE, Gates LK, Perrault J, Whitcomb DC, et al. hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst. 1997;89:442–446
  31. Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer: From genes to families. Surg Oncol Clin N Am. 1998;7:1–23
  32. Eberle MA, Pfutzer R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, et al.  A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32–34. Am J Hum Genet. 2002;70:1044–1048
  33. Slack JMW. Developmental biology of the pancreas. Development. 1995;121:1569–1580
  34. Edlund H. Pancreas: how to get there from the gut?. Curr Opin Cell Biol. 1999;11:663–668
  35. Means AL, Leach SD. Lineage commitment and cellular differentiation in exocrine pancreas. Pancreatology. 2001;1:587–596
  36. Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, et al.  Notch signaling controls pancreatic cell differentiation. Nature. 1999;400:877–881
  37. Jensen J, Perdersen EE, Galante P, Hald J, Heller RS, Ishibashi M, et al.  Control of endodermal endocrine development by Hes-1. Nat Genet. 2000;24:36–43
  38. Crisera CA, Kadison AS, Breslow GD, Maldonado TS, Longaker MT, Gittes GK. Expression and role of laminin-1 in mouse pancreatic organogenesis. Diabetes. 2000;49:936–944
  39. Gittes GK, Galante PE, Hanahan D, Rutter WJ, Debase HT. Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. Development. 1996;122:439–447
  40. Miralles F, Czernichow P, Scharfmann R. Follistatin regulates the relative proportions of endocrine versus exocrine tissue during pancreatic development. Development. 1997;125:1017–1024
  41. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, et al.  Pdx-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development. 1996;122:983–995
  42. St-Onge L, Sosa-Pineda B, Chowdhury K, et al.  Pax6 is required for differentiation of glucagon-producingα-cells in mouse pancreas. Nature. 1997;387:406–409
  43. Song SY, Gannon M, Washington MK, et al.  Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing TGFα. Gastroenterology. 1999;117:1416–1426
  44. Meszoely IM, Means AL, Scoggins CR, Leach SD. Developmental aspects of early pancreatic cancer. Cancer J. 2001;7:242–250
  45. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC. Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell. 1990;61:1121–1135
  46. Wagner M, Greten FR, Weber CK, Koschnick S, Mattfeldt T, Deppert W, et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 2001;15:286–293
  47. Parker SL, Tong T, Bolden S, Wingo PA, Cancer Statistics . CA Cancer J Clin. 1997;47:5–27
  48. Yeo CJ, Cameron JL, Lillemoe KD, et al.  Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221:721–733
  49. Hruban RH, Adsay NV, Albores-Saavedra J, et al.  Pancreatic intraepithelial neoplasia (PanIN): a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579–586
  50. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma): a clinicopathologic study of 41 cases. Am J Clin Pathol. 1978;69:573–580
  51. Sessa F, Capella C, Kloppel K, Zamboni G, Scarpa A, Bonato MS. K-ras gene mutation in intraductal neoplasms of the pancreas. Lab Invest. 1994;70(788):135A
  52. Seidel G, Zahurak M, Iacobuzio-Donahue C, et al.  Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol. 2001;26:56–63
  53. Wilentz RE, Goggins M, Redston M, et al.  Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. Am J Pathol. 2000;156:1641–1651
  54. Goggins M, Offerhaus GJA, Hilgers W, et al.  Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998;152:1501–1507
  55. Wilentz RE, Chung CH, Sturm PDJ, et al.  K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer. 1998;82:96–103
  56. Hahn SA, Schutte M, Hoque ATMS, et al.  DPC4, a candidate tumor suppressor gene at human chromosome 18q211. Science. 1996;271:350–353
  57. Wilentz RE, Su GH, Dai JL, et al.  Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic: a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37–43
  58. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690–2698
  59. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22:163–169
  60. Hruban RH, Offerhaus GJA, Kern SE, Goggins M, Wilentz RE, Yeo CJ. Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg. 1998;5:383–391
  61. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002–2006
  62. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54:3568–3573
  63. Wilentz RE, Albores-Saavedra J, Zahurak M, et al.  Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 1999;23:1320–1327
  64. Thompson LDR, Becker RC, Przygodzki RM, Adair CF, Heffess CS. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of the pancreas. Am J Surg Pathol. 1999;23:1–16
  65. Tada M, Omata M, Ohto M. Ras gene mutations in intraductal papillary neoplasms of the pancreas: analysis in five cases. Cancer. 1991;67:634–637
  66. Fujii H, Inagaki M, Kasai S, et al.  Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 1997;151:1447–1454
  67. Iacobuzio-Donahue CA, Klimstra D, Adsay NV, et al.  DPC-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal carcinomas. Am J Pathol. 2000;157:755–761
  68. Buchino JJ, Castello FM, Nagaraj HS. Pancreatoblastoma: a histochemical and ultrastructural analysis. Cancer. 1984;53:963–969
  69. Abraham SC, Wu TT, Klimstra DS, et al.  Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol. 2001;159:1619–1627
  70. Belsky H, Cornell NW. Disseminated focal fat necrosis following radical pancreatico-duodenectomy for acinous carcinoma of head of pancreas. Ann Surg. 1955;141:556–562
  71. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas: a clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815–837
  72. Abraham SC, Wu TT, Hruban RH, et al.  Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol. 2002;160:953–962
  73. Learmonth GM, Price SK, Visser AE, Emms M. Papillary and cystic neoplasm of the pancreas—an acinar cell tumour?. Histopathology. 1985;9:63–79
  74. Abraham SC, Klimstra DS, Wilentz RE, et al.  Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol. 2002;160:1361–1369
  75. Hruban RH, van Mansfield ADM, Offerhaus GJA, van Weering DHJ, Allison DC, Goodman SN, et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545–554
  76. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant K-ras genes. Cell. 1998;53:549–554
  77. Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, et al.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas. Am J Pathol. 2000;156:1641–1651
  78. Wilentz RE, Chung DH, Sturn PDJ, Musler A, Sohn TA, Offerhaus GJA, et al.  K-ras mutations in duodenal fluid of patients with pancreas carcinoma. Cancer. 1998;82:96–103
  79. Boadas J, Mora J, Urgell E, Puig P, Roca M, Cusso X, et al.  Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. Eur J Gastroenterol Hepatol. 2001;13:1153–1159
  80. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal mucinous cell hyperplasia. Cancer Res. 1994;54:3568–3573
  81. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al.  Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996;93:3636–3641
  82. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Buchler M, et al.  Characterization of a high copy number amplification of 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 1997;57:3135–3139
  83. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27–32
  84. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126–3130
  85. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA. 1999;96:14517–14522
  86. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al.  14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997;1:3–11
  87. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al.  DPC4, a candidate tumor-suppressor gene at human chromosome 18q211. Science. 1996;271:350–353
  88. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al.  Human Smad3 and Smad4 are sequence specific transcription activators. Mol Cell. 1998;1:611–617
  89. Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, et al.  ACVR1B (ALK4, activin receptor type IB) gene mutations in pancreatic cancer. Proc Natl Acad Sci USA. 2001;98:3254–3257
  90. Su GH, Hilgers W, Shekher M, Tang D, Yeo CJ, Hruban RH, et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998;58:2339–2342
  91. Teng DHF, Perry WL, Hogan JK, Baumgard M, Bell R, Berry S, et al.  Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997;57:4177–4182
  92. Su GH, Hruban RH, Bansal RK, Bova DS, Tang DJ, Shekher MC, et al.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999;154:1835–1840
  93. Goggins M, Offerhaus GJ, Hilgers W, Griffin CA, Shekher M, Tang D, et al.  Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998;152:1501–1507
  94. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Peterson GM, et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364
  95. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000;156:1767–1771
  96. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–1249
  97. Argani P, Iacobuzio-Donahue C, Ryu B, Goggins M, Rosty C, Wilentz RE, et al.  Mesothelin is expressed in the vast majority of adenocarcinomas of the pancreas: identification of a new cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–3868
  98. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SD, Leach SD, et al.  Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61:4320–4324
  99. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, et al.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45–50
  100. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868–1875
  101. Iacobuzio-Donahue CA, Maitra A, Olsen M, van Heek T, Rosty C, Walter K, et al. Exploration of global gene expression of pancreatic adenocarcinoma by cDNA microarray analysis. Am J Pathol [In press].
  102. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, et al.  Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819–826
  103. Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res. 2001;61:1833–1838
  104. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol. 2002;160:91–99
  105. Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, et al.  The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37–47
  106. Fishman EK, Horton KM, Urban BA. Multidetector CT angiography in the evaluation of pancreatic carcinoma: preliminary observations. J Comput Assist Tomogr. 2000;24:849–853
  107. Bluemke DA, Cameron JL, Hruban RH, Pitt HA, Siegelman SS, Soyer P, et al.  Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology. 1995;197:381–385
  108. Rosch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, et al.  Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology. 1992;102:188–199
  109. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, et al.  Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 1998;170:1315–1322
  110. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784–1791
  111. Ariyama J, Suyama M, Satoh K, Wakabayashi K. Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors. Abdom Imaging. 1998;23:380–386
  112. Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, et al.  Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999;44:1039–1046
  113. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247–255
  114. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95:11891–11896
  115. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, et al.  Detection of breast cancer cells in ductal lavage fluid by methylation- specific PCR. Lancet. 2001;357:1335–1336
  116. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, et al.  Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res. 1998;4:1527–1532
  117. Mulcahy HE, Lyautey J, Lederrey C, qi Chen X, Anker P, Alstead EM, et al.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 1998;4:271–275
  118. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  119. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229
  120. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–1839
  121. Ueki T, Toyota M, Skinner HG, Walter KM, Yeo CJ, Issa J-PP , et al.  Identification and characterization of differentially methylated CpG islands in pancreatic cancer. Cancer Res. 2001;61:8540–8546
  122. Iwao T, Hiyama E, Yokoyama T, Tsuchida A, Hiyama K, Murakami Y, et al.  Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst. 1997;89:1621–1623
  123. Iacobuzio-Donahue CA AM, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–1249
  124. Byungwoo Ryu JJ, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819–826
  125. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–3868
  126. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868–1875
  127. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al.  Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  128. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609–3614
  129. In: Exocrine pancreas. AJCC Cancer Staging Manual. 6th edition. New York: Springer; 2002;p. 157–163
  130. UICC . TNM classification of malignant tumors. 4th ed. New York: : Springer Verlag; 1987;
  131. Japan Pancreas Society . General rules for surgical and pathological studies on cancer of the pancreas. 3rd ed. Tokyo: : Kanehara; 1987;
  132. Cujik J, Babiker AG. Pancreatic cancer, diabetes mellitus and gallbladder disease. Int J Cancer. 1989;43:415–421
  133. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathological entity. Ann Surg. 2001;234:313–322
  134. Ritts RE, Pitt HA. CA19-9 in pancreatic cancer. Surg Oncol Clin North Am. 1998;7:93–101
  135. Ritts R, Nagorney D, Jacobsen D, et al.  Comparison of preoperative CA19-9 levels with results of other diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic cancer or gallbladder disease. Pancreas. 1994;9:707–716
  136. Willett C, Daly W, Warshaw A. CA19-9 is an index of response to neoadjuvant chemoradiation in pancreatic cancer. Am J Surg. 1996;172:350–352
  137. Bluemke DA, Abrams RA, Yeo CJ, et al.  Recurrent pancreatic adenocarcinoma: Spiral CT evaluation following the Whipple procedure. RadioGraphics. 1997;17:303–313
  138. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–1249
  139. Argani P, Iacobuzio-Donahue C, Ryu B, et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–3868
  140. Argani P, Rosty C, Reiter RE, et al.  Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61:4320–4324
  141. Horton KM. Multidetector CT and three-dimensional imaging of the pancreas: state of the art. J Gastrointest Surg. 2002;6:126–128
  142. Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cancer. Surg Oncol Clin North Am. 1998;7:103–124
  143. Trede M, Rumstadt B, Wendl K, et al.  Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors. Ann Surg. 1997;226:393–407
  144. Reinhold C. Magnetic resonance imaging of the pancreas in 2001. J Gastrointest Surg. 2002;6:133–135
  145. Rosch T, Lorenz R, Braig C, et al.  Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc. 1991;37:347–352
  146. Snady H, Cooperman A, Siegel J. Endoscopic ultrasound compared with computed tomography with ERCP in patients with obstructive jaundice or small peri-pancreatic mass. Gastrointest Endosc. 1992;38:27–34
  147. Muller MF, Meyenberger C, Bertschinger P, et al.  Pancreatic tumors: evaluation with endoscopic US, CT and MR imaging. Radiology. 1994;190:745–757
  148. Stevens PD, Lightdale CJ. The role of endosonography in the diagnosis and management of pancreatic cancer. Surg Oncol Clin North Am. 1998;7:125–133
  149. Wiersema MJ, Vilman P, Giovannini M, et al.  Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology. 1997;112:1087–1089
  150. Wiersema MJ. Endoscopic ultrasonography. J Gastrointest Surg. 2002;6:129–132
  151. Baron PL, Aabakken LE, Cole DJ, et al.  Differentiation of benign from malignant masses by endoscopic ultrasound. Ann Surg Oncol. 1997;4:639–643
  152. Mertz HR, Sechopoulos P, Delbeke D, et al.  EUS, PET and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc. 2000;52:367–371
  153. Gress F, Gottlieb K, Sherman S, et al.  Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer. Ann Intern Med. 2001;134:459–464
  154. Inokuma T, Tamaki N, Torizuka T, et al.  Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med. 1995;36:229–235
  155. Alazraki N. Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastrointest Surg. 2002;6:136–138
  156. Rose DM, Delbeke D, Beauchamp RD, et al.  18-fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999;229:729–737
  157. Barreiro CJ, Lillemoe KD, Koniaris LG, et al.  Diagnostic laparoscopy for periampullary and pancreatic cancer: What is the true benefit?. J Gastrointest Surg. 2002;6:75–81
  158. Bemelman WA, de Wit LTh, van Delden OM, et al.  Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region. Br J Surg. 1995;82:820–824
  159. Callery MP, Strasberg SM, Doherty GM, et al.  Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg. 1997;185:33–39
  160. Andren-Sandberg A, Lindberg CG, Lundstedt C, et al.  Computed tomography and laparoscopy in the assessment of the patient with pancreatic cancer. J Am Coll Surg. 1998;186:35–40
  161. Conlon KC, Dougherty E, Klimstra DS, et al.  The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223:134–140
  162. John TG, Greig JD, Carter DC, et al.  Carcinoma of the pancreatic head and periampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg. 1995;221:156–164
  163. Fernandez-del Castillo C, Warshaw AL. Laparoscopic staging and peritoneal cytology. Surg Oncol Clin North Am. 1998;7:135–142
  164. Soehendra N, Reynders-Frederix V. Palliative bile duct drainage—a new endoscopic method of introducing a transpapillary drain. Endoscopy. 1980;12:8–10
  165. Lichtenstein DR, Carr-Locke DL. Endoscopic palliation for unresectable pancreatic cancer. Surg Clin North Am. 1995;75:969–988
  166. Molnar W, Stockum AE. Relief of obstructive jaundice through percutaneous transhepatic catheter: a new therapeutic method. AJR Am J Roentgenol. 1974;122:356–367
  167. Kaufman SL. Percutaneous palliation of unresectable pancreatic cancer. Surg Clin North Am. 1995;75:989–999
  168. Speer AG, Cotton PB, Russell RCG, et al.  Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet. 1987;2:57–62
  169. Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg. 1992;79:8–20
  170. Lillemoe KD. Palliative therapy for pancreatic cancer. Surg Oncol Clin North Am. 1998;7:199–216
  171. Levy MH. Pharmacology treatment of cancer pain. N Engl J Med. 1996;335:1124–1132
  172. Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery. 1983;91:123–133
  173. Singh SM, Reber HA. Surgical palliation for pancreatic cancer. Surg Clin North Am. 1989;69:599–611
  174. Lillemoe KD, Cameron JL, Hardacre JM, et al.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230:322–330
  175. Copping J, Willix R, Kraft R. Palliative chemical splanchnicectomy. Arch Surg. 1978;113:509–511
  176. Lillemoe KD, Cameron JL, Kaufman HS, et al.  Chemical splanchnicectomy in patients with unresectable pancreatic cancer: A prospective randomized trial. Ann Surg. 1993;217:447–457
  177. Sohn TA, Lillemoe KD, Cameron JL, et al.  Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg. 1999;188:658–669
  178. Kausch W. Das Carcinom der Papilla Duodeni und seine radikale Entfeinung. Beitrage zur Klinische Chirurgie. 1912;78:439–486
  179. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg. 1935;102:763–779
  180. Traverso LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet. 1978;146:959–962
  181. Yeo CJ, Cameron JL, Sohn TA, et al.  Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229:613–624
  182. Sohn TA, Yeo CJ, Cameron JL, et al.  Resected adenocarcinoma of the pancreas—616 patients: results, outcomes and prognostic indicators. J Gastrointest Surg. 2000;4:567–579
  183. Yeo CJ, Cameron JL, Lillemoe KD, et al.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg. 2002;236:355–368
  184. Nguyen TC, Sohn TA, Cameron JL, et al. Standard versus radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg [In press].
  185. Cameron JL. Rapid exposure of the portal and superior mesenteric veins. Surg Gynecol Obstet. 1993;176:395–398
  186. Yeo CJ. The Whipple procedure in the 1990s. Adv Surg. 1999;32:271–303
  187. Yeo CJ. Surgical management: standard Whipple procedure. In:  Cameron JL editors. Atlas of clinical oncology: pancreatic cancer. Hamilton: BC Decker; 2001;p. 99–108
  188. Pikarsky AJ, Muggia-Sullam M, Eid A, et al.  Pancreaticogastrostomy after pancreaticoduodenectomy: a retrospective study of 28 patients. Arch Surg. 1997;132:296–299
  189. Yamamoto J, Shimamura Y, Nakahara H, et al.  Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis. Arch Surg. 1997;132:785–788
  190. Yeo CJ, Cameron JL, Maher MM, et al.  A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 1995;222:580–592
  191. Trede M, Schwall G, Saeger H-D. Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447–458
  192. Yeo CJ, Cameron JL, Sohn TA, et al.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, outcomes. Ann Surg. 1997;226:248–260
  193. Yeo CJ. Management of complications following pancreaticoduodenectomy. Surg Clin North Am. 1995;75:913–924
  194. Sohn TA, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy: the role of interventional radiologists in managing patients and complications. J Gastrointest Surg [In press].
  195. Yeo CJ, Cameron JL. Pancreatic cancer: current controversies. In:  Schein M,  Wise L editor. Clinical Controversies in Surgery. Basel, Switzerland: Karger Landes; 1998;p. 70–77
  196. Satake K, Nishiwaki H, Yokomatsu H, et al.  Surgical curability and prognosis for standard versus extended resections for T1carcinoma of the pancreas. Surg Gynecol Obstet. 1992;175:259–265
  197. Manabe T, Ohshio G, Baba N, et al.  Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer. 1989;64:1132–1137
  198. Pedrazzoli S, DiCarlo V, Dionigi R, et al.  Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective, randomized study. Ann Surg. 1998;228:508–517
  199. Sperti C, Pasquali C, Pedrazzoli S. Ductal adenocarcinoma of the body and tail of the pancreas. J Am Coll Surg. 1997;185:255–259
  200. Wade TP, Virgo KS, Johnson FE. Distal pancreatectomy for cancer: results in US Department of Veterans Affairs Hospitals, 1987-1991. Pancreas. 1995;11:341–344
  201. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903
  202. Gastrointestinal Tumor Study Group . A multi institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic carcinoma. Ann Surg. 1979;189:205–208
  203. Gastrointestinal Tumor Study Group . Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–2010
  204. Gastrointestinal Tumor Study Group . Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–755
  205. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann Surg. 1997;225:621–636
  206. Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak M, Haulk TL, et al.  Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999;44:1039–1046
  207. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous infusion 5-fluorouracil, mitomycin-c, leukovorin and dipyridamole. J Gastrointest Surg. 1998;2:159–166
  208. Abrams RA, Korman LT, Yeo CJ, Jaffee E, Chakravarthy A, Zahurak ML, et al.  Intensified adjuvant therapy for periampullary (pancreatic, nonpancreatic) adenocarcinoma using irradiation, 5-FU, mitomycin C, leukovorin and dipyridamole (J9625)-updated results. ASTRO Proc. 2000;48:222a
  209. Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al.  Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2000;48:1483–1487
  210. Nukui Y, Picozzi VJ, Traverso LW. Interferon based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000;179:367–371
  211. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776–784
  212. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet. 2001;358:1576–1585
  213. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by Gemcitabine. Oncology. 1999;13(Suppl 5):55–60
  214. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al.  Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208–2212
  215. Blackstock AW, Tempero MA, Niedwiecki D, Hollis DR, Mayer RJ, Tepper JE. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Proc ASCO. 2001;20:158a; [abstract 627]
  216. Hoffman JP, McGinn CJ, Szarka C, Morphis J, Cooper HS, Wilkes J, et al.  A phase I study of pre-operative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized resectable pancreatic adenocarcinoma. Proc ASCO. 1998;17:283a; [abstract 1090]
  217. McGinn CJ, Smith DC, Szarka C, Pinover WH, Loehrer PJ, Morphis JG, et al.  A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer. Proc ASCO. 1998;17:265a; [abstract 1014]
  218. McGinn CJ, Zalupski MM. Combined modality therapy in pancreatic cancer: current status and future directions. Cancer J. 2001;7:338–348
  219. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PWT, Lee JE, et al.  Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Can Res. 2001;2246:2246–2253
  220. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DM, et al.  Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202–4208
  221. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, et al.  Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000;18:3384–3389
  222. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic cancer: a prospective randomized phase II study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902–910
  223. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al.  Phase II trial of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569–577
  224. Symon Z, Davis M, McGinn CJ, Zalupski MM, Lawrence TS. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys. 2002;53:140–145
  225. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al.  Is the therapeutic index better with gemcitabine based chemoradiation than with 5-fluorouracil based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys. 2002;52:1293–1302
  226. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928–937
  227. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:317–323
  228. Arnoletti JP, Hoffman JP, Ross EA, Kagan SA, Meropol NJ, Freedman G, et al.  Pre-operative chemoradiationin the management of adenocarcinoma of the body of the pancreas. Am Surg. 2002;68:330–335
  229. Pisters PWT, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al.  Preoperative paclitaxel and concurrent rapid fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates and event-free outcome. J Clin Oncol. 2002;20:2537–2544
  230. Abbruzzese JL, Rosenberg A, Xiong Q, LoBuglio A, Schmidt W, Wolff R, et al.  Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with Gemcitabine in patients with advanced pancreatic cancer. Proc ASCO. 2001;20:130a; [abstract 518]
  231. Bos JL. Rasoncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  232. Hruban RH, Van Mansfeld AD, Offerhaus GJ, VanWeering DH, Allison D, Goodman SN, et al.  K-ras oncogene activation in adenocarcinoma of the pancreas. Am J Path. 1993;143:545–554
  233. Khleif SN, Abrams S, Allegra C, Bastian A, Bergmann E, Bernstein S, et al.  The generation of CD4+ and CD8+ T cell responses from patients vaccinated with mutant ras peptides corresponding to the patient's own ras mutation. Proc ASCO. 1997;16:437a; [abstract 1566]
  234. Wojtowicz ME, Hamilton MJ, Bernstein S, McNally D, Chatfield S, Edison M, et al.  Clinical trial of mutant ras peptide vaccination along with IL-2 or GM-CSF. Proc ASCO. 2000;20:463a; [abstract 1818]
  235. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaus I, Soreide O, et al.  Intradermal ras peptide vaccination with granulocyte-macrophage colony stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92:441–450
  236. Lewis JJ, Janetzki S, Livingston PO, Desantis D, Williams L, Klimstra D, et al.  Pilot trial of vaccination with autologous tumor derived gp96 heat shock protein -peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma. Proc ASCO. 1999;19:438a; [abstract 1687]
  237. Pardoll DM, Jaffee EM. Cancer vaccines: clinical applications. In: 3rd ed.  Rosenberg SA editors. The principles and practice of the biologic therapy of cancer. Philadelphia: Lippincott Williams and Wilkens; 2000;p. 647–662
  238. Dranoff G, Jaffee EM, Lazenby A, Golumbek P, Levistky H, Brose K, et al.  Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543
  239. Huang AY, Golumbek PT, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow derived cells in presenting MHC class I restricted tumor antigens. Science. 1994;264:961–965
  240. Nakazaki Y, Tani K, Lin ZT, Sumimoto H, Hibino H, Tanabe T, et al.  Vaccine effect of granulocyte-macrophage colony stimulating factor or CD80 gene transduced murine hematopoietic tumor cells and their cooperative enhancement of anti-tumor immunity. Gene Ther. 1998;5:1355–1362
  241. Simons JW, Jaffee EM, Weber C, Levitsky H, Nelson W, Carducci M, et al.  Bioactivity of human GM-CSF gene transduced autologous renal vaccines. Cancer Res. 1997;57:1537–1546
  242. Jaffee EM, Hruban R, Biedzycki B, Laheru D, Schepers K, Sauter P, et al.  A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145–156
  243. Snozl M, Marincola FM. Cancer vaccines: basic principles. In: 3rd ed.  Rosenberg SA editors. The principles and practice of the biologic therapy of cancer. Philadelphia: Lippincott Williams and Wilkens; 2000;p. 617–631
  244. Berd D, Maguire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986;46:2572–2577
  245. Machiels JP, Reilly RT, Emens L, Ercolini A, Lei R, Weintraub D, et al.  Cyclophosphamide, doxorubicin, and Paclitaxel enhance the anti-tumor immune response of GM-CSF secreting whole cell vaccines in tolerized mice. Cancer Res. 2001;61:3689–3697
  246. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, et al.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest. 1998;101:429–441
  247. Nowak AK, Robinson BWS, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002;62:2353–2358
  248. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–193
  249. Malcolm J, Moore JH, Eisenberg P, Dagenais M, Hagan K, Fields A, et al.  A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic. Proceedings of the American Society of Clinical Oncology. 2000;19
  250. Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, et al.  A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer. 2001;85:1865–1870
  251. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447–3455
  252. Adjei A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062–1074
  253. Cohen SJ, Ranganathan S, Lewis N, Rogatko A, Weiner LM, Alpaugh K, et al. Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol [In press].
  254. Macdonald JS, Whitehead R, Wade J, Giguere J, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol [In press].
  255. Van Cutsem E, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol [In press].
  256. Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer. 2002;26:109–164
  257. Abbruzzese JL, Xiong Q, Lo Buglio A, Schmidt W, Wolff R, Needle M, et al.  Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2001;
  258. Safran , HSchwartz J, King TC, Steinhoff MM, Nauman C, Hesketh P, et al.  Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol. 2001;

PII: S0147-0272(02)50015-5

doi: 10.1067/mcn.2002.129579

Current Problems in Cancer
Volume 26, Issue 4 , Pages 176-275 , July 2002

Article Tools

* Image Usage & Resolution